Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00391729 · ClinicalTrials.gov registry record · Phase 2

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by Abbott.

Completed
Registry status
Phase 2
Development phase
221
Enrollment target
20
Study locations

NCT00391729: Completed Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by Abbott.

NCT00391729 is a Phase 2 study of Attention Deficit Hyperactivity Disorder that has completed, run by Abbott. The registered enrollment target is 221 participants, roughly in line with the 214-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00391729, a Phase 2 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 2
Development phase
221 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.

Conditions Studied

Attention Deficit Hyperactivity Disorder

Interventions

  • DRUG Placebo
  • DRUG ABT-089

Study Locations (20)

Florida

  • - Jacksonville
  • - Maitland
  • - Miami
  • - Tampa

California

  • - Lafayette
  • - Oceanside
  • - San Diego

New York

  • - New York
  • - Staten Island

Arizona

  • - Mesa

Colorado

  • - Denver

Kansas

  • - Newton

Michigan

  • - Farmington Hills

Nebraska

  • - Omaha

Trial Details

FieldValue
Enrollment Target 221 participants
Start Date 2006-10
Est. Completion 2007-06
Phase Phase 2
Abbott

181 total trials

What the finished NCT00391729 record still lists

NCT00391729 is an interventional study that assigns participants to a tested intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 214-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target.

The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00391729 names 20 study sites across 14 states, led by Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT00391729 about?

NCT00391729 is a clinical study titled "A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.

What is the current status of trial NCT00391729?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2006-10. Estimated completion is 2007-06.

What conditions does trial NCT00391729 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.

What interventions are being tested in trial NCT00391729?

The interventions under investigation include: Placebo (DRUG), ABT-089 (DRUG).

Who is sponsoring clinical trial NCT00391729?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00391729 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00391729's enrollment target sits among peer trials

221 30th of 102 higher than 73 of 102 other Attention Deficit Hyperactivity Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03170440 · 221 participants · NA

    Non-invasive Nerve Stimulation for PTSD and Sleep

  • NCT04939610 · 222 participants · Phase 1

    A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

  • NCT05424783 · 222 participants

    MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

  • NCT05568264 · 222 participants · NA

    Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00391729, the US trial registry maintained by the National Library of Medicine. NCT00391729 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.